摘要:
Compounds I and II that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
摘要:
Hydrindane analogs of formula (IA) and (IB) that have agonist activity at one or more of the SlP receptors are provided. The ' compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
摘要:
Compounds and methods useful for preventing and treating pain,e.g., neuropathic pain, in a subject in need thereof are provided. The compounds can be "SlP modulating" agents that are capable of inducing a detectable change in SlP receptor activity.
摘要:
The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.
摘要:
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
摘要:
The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure of Formula (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and -NH(CO)-; R2 is selected from the group consisting of H, C1 -C4 alkyl, (C1 -C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is selected from the group consisting of hydroxy, phosphonate, and of Formula (II) wherein X and R12 is selected from the group consisting of O and S; or a pharmaceutically acceptable salt or tautomer thereof.
摘要:
The present invention provides compounds that have antagonist activity at the S1P 1 and/or S1P 3 receptors. These compounds have enhanced selectivity and potency at the S1P 1 and/or S1P 3 receptors.
摘要:
Sphingosine-1 -phosphate analogs that are potent, and selective agonists at one or more SlP receptors, specifically the S1P1 receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha- substituted phosphonates, and phosphothionates.
摘要:
The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R 11 is C 5 -C 18 alkyl or C 5 -C 18 alkenyl; Q is selected from the group consisting of C 3 -C 6 optionally substituted cycloalkyl, C 3 -C 6 optionally substituted heterocyclic, C 3 -C 6 optionally substituted aryl C 3 -C 6 optionally substituted heteroaryl and; R 2 is selected from the group consisting of H, C 1 -C 4 alkyl, (C 1 -C 4 alkyl)OH and (C 1 -C 4 alkyl)NH 2 ; R 23 is H or C 1 -C 4 alkyl, and R 15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.
摘要:
Benzocycloheptyl analogs that have agonist activity at one or more of the S IP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.